Mostra 1 - 1 risultati di 1 ricerca 'on behalf of the FUTURE 2 study group', tempo di risposta: 0,02s
Raffina i risultati
-
1
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... di L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group
Pubblicazione 2018-12-01
Articolo